Dali Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dali Cheng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Chengguang Sui
Department of Biotherapy, Cancer Research Institute The First Affiliated Hospital of China Medical University Shenyang Liaoning China
3 shared publicationsFandong Meng
Department of Biotherapy, Cancer Research Institute, The First Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publicationsYan Li
Department of Biotherapy, Cancer Research Institute, The First Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publicationsYang Wang
Department of Biotherapy, Cancer Research Institute, The First Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publications- Fandong Meng
Department of Biotherapy, Cancer Research Institute The First Affiliated Hospital of China Medical University Shenyang Liaoning China
1 shared publication Guiyan Ma
Outpatient Blood Collection Center The First Affiliated Hospital of China Medical University Shenyang Liaoning China
1 shared publication
Latest Publications
- 8 December 2022
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 37 (3) , e23264
Hsa_circ_0000119 promoted ovarian cancer development via enhancing the methylation of CDH13 by sponging miR‐142‐5p
Ovarian cancer is the leading cause of gynecological cancer‐related death in women, and is difficult to treat. The aim of our study is to explore the role and action mechanism of hsa_circ_0000119 in ovarian cancer, thus to analyze whether the circular RNA is a potential target for the treatment of the disease. In this present study, our data shows that hsa_circ_0000119 and DNA methyltransferase 1 (DNMT1) was increased, while miR‐142‐5p was decreased in ovarian cancer. Overexpression of hsa_circ_0000119 promoted tumor growth, while silencing of hsa_circ_0000119 resulted in an opposite effects. Decreasing of hsa_circ_0000119 also notably inhibited the proliferation, migration, and invasion of the ovarian cancer cells. Moreover, the data proves that hsa_circ_0000119 negatively regulated miR‐142‐5p and cadherin 13 (CDH13) expression, but positively regulated DNMT1 expression. miR‐142‐5p could interact with hsa_circ_0000119 and DNMT1 3′‐UTR. Silencing of DNMT1 could reverse the inhibition of hsa_circ_0000119 to miR‐142‐5p and CDH13 expression. Importantly, higher level of CDH13 promoter methylation existed in the ovarian tumors than that in matched normal tissues. DNA methyltransferase inhibitor could increase the expression of CDH13 in ovarian cancer cells. In addition, our results also prove that increasing of CDH13 or miR‐142‐5p effectively reversed the inhibition of hsa _circ_0000119 to the cell malignant phenotypes. Overall, our data demonstrate that hsa_circ_0000119 facilitated ovarian cancer development through increasing CDH13 expression via promoting DNMT1 expression by sponging miR‐142‐5p. Our data demonstrate the potential role of hsa_circ_0000119 in the treatment of ovarian cancer.
- 8 December 2022
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 37 (3) , e23264
Hsa_circ_0000119 promoted ovarian cancer development via enhancing the methylation of CDH13 by sponging miR‐142‐5p
Ovarian cancer is the leading cause of gynecological cancer‐related death in women, and is difficult to treat. The aim of our study is to explore the role and action mechanism of hsa_circ_0000119 in ovarian cancer, thus to analyze whether the circular RNA is a potential target for the treatment of the disease. In this present study, our data shows that hsa_circ_0000119 and DNA methyltransferase 1 (DNMT1) was increased, while miR‐142‐5p was decreased in ovarian cancer. Overexpression of hsa_circ_0000119 promoted tumor growth, while silencing of hsa_circ_0000119 resulted in an opposite effects. Decreasing of hsa_circ_0000119 also notably inhibited the proliferation, migration, and invasion of the ovarian cancer cells. Moreover, the data proves that hsa_circ_0000119 negatively regulated miR‐142‐5p and cadherin 13 (CDH13) expression, but positively regulated DNMT1 expression. miR‐142‐5p could interact with hsa_circ_0000119 and DNMT1 3′‐UTR. Silencing of DNMT1 could reverse the inhibition of hsa_circ_0000119 to miR‐142‐5p and CDH13 expression. Importantly, higher level of CDH13 promoter methylation existed in the ovarian tumors than that in matched normal tissues. DNA methyltransferase inhibitor could increase the expression of CDH13 in ovarian cancer cells. In addition, our results also prove that increasing of CDH13 or miR‐142‐5p effectively reversed the inhibition of hsa _circ_0000119 to the cell malignant phenotypes. Overall, our data demonstrate that hsa_circ_0000119 facilitated ovarian cancer development through increasing CDH13 expression via promoting DNMT1 expression by sponging miR‐142‐5p. Our data demonstrate the potential role of hsa_circ_0000119 in the treatment of ovarian cancer.
- 10 November 2022
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 17 (3) , 627-638
CircRNA hsa_circ_0001627 aggravates cervical cancer progression through upregulation of FNDC3B and activating PI3K/mTOR signaling pathway
Circular RNAs (CircRNAs) are key regulators in the development and progression of human cancers. However, the biological roles and mechanisms of circRNAs in gastric cancer (GC) remain largely unknown. Analyzing circRNA microarray dataset (GSE102686) and clinical specimens, a novel circRNA termed hsa_circ_0001627, was identified and it was highly expressed in CC cancerous tissues and cells, and was associated with poor clinical outcomes. Functionally, hsa_circ_0001627 silencing impaired the malignant progression of CC cells and the growth of CC xenografts in nude mice. Mechanistically, hsa_circ_0001627 acted as a miR-1225-5p sponge, thus indirectly regulating FNDC3B and leading to the activation of PI3K/mTOR signaling pathway. Collectively, the present study indicates that hsa_circ_0001627 regulates miR-1225-5p/FNDC3B/PI3K/mTOR axis and functions as an oncogene in CC progression, suggesting the potential therapeutic use of hsa_circ_0001627 in CC treatment.
- 10 November 2022
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 17 (3) , 627-638
CircRNA hsa_circ_0001627 aggravates cervical cancer progression through upregulation of FNDC3B and activating PI3K/mTOR signaling pathway
Circular RNAs (CircRNAs) are key regulators in the development and progression of human cancers. However, the biological roles and mechanisms of circRNAs in gastric cancer (GC) remain largely unknown. Analyzing circRNA microarray dataset (GSE102686) and clinical specimens, a novel circRNA termed hsa_circ_0001627, was identified and it was highly expressed in CC cancerous tissues and cells, and was associated with poor clinical outcomes. Functionally, hsa_circ_0001627 silencing impaired the malignant progression of CC cells and the growth of CC xenografts in nude mice. Mechanistically, hsa_circ_0001627 acted as a miR-1225-5p sponge, thus indirectly regulating FNDC3B and leading to the activation of PI3K/mTOR signaling pathway. Collectively, the present study indicates that hsa_circ_0001627 regulates miR-1225-5p/FNDC3B/PI3K/mTOR axis and functions as an oncogene in CC progression, suggesting the potential therapeutic use of hsa_circ_0001627 in CC treatment.
- 2 March 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 477 (6) , 1669-1679
CircWHSC1 expedites cervical cancer progression via miR-532-3p/LTBP2 axis
Dysregulated circRNAs have potential roles in the progression of various cancer types, including cervical cancer (CaCx). The carcinogenic roles of circRNA Wolf–Hirschhorn syndrome candidate gene-1 (circWHSC1) are described in the development of diverse cancers. The objective of this study was to investigate the expression and the underlying role of circWHSC1 in CaCx. The expression of circWHSC1 was detected by real-time PCR. After the suppression of circWHSC1 expression, the changes in the proliferation, migration, invasion, and apoptosis capacities were detected by CCK-8 assay, colony formation assay, Transwell assays, flow cytometry, and the determination of apoptosis-related proteins. The interplay among circWHSC1, miR-532-3p, and latent transforming growth factor-β binding protein 2 (LTBP2) was confirmed by luciferase reporter and biotinylated RNA pull-down assays. A nude mice xenograft tumor model was established to evaluate the anti-tumorigenic role of circWHSC1 silencing in vivo. CircWHSC1 was overexpressed in CaCx tissues and cell lines and its high expression was inversely associated with the survival rate of patients with CaCx. CircWHSC1 silencing was capable of suppressing the proliferation, metastasis, and invasion of tumor cells and inducing apoptosis. Investigation to its molecular mechanism revealed that circWHSC1 functioned as a competitive endogenous RNA (ceRNA), mediating LTBP2 expression by targeting miR-532-3p. The in vivo experiments further confirmed the inhibition of tumor growth and metastasis by circWHSC1 knockdown. The circWHSC1-mediated miR-532-3p/LTBP2 signaling axis might be a novel therapeutic target for CaCx.
- 2 March 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 477 (6) , 1669-1679
CircWHSC1 expedites cervical cancer progression via miR-532-3p/LTBP2 axis
Dysregulated circRNAs have potential roles in the progression of various cancer types, including cervical cancer (CaCx). The carcinogenic roles of circRNA Wolf–Hirschhorn syndrome candidate gene-1 (circWHSC1) are described in the development of diverse cancers. The objective of this study was to investigate the expression and the underlying role of circWHSC1 in CaCx. The expression of circWHSC1 was detected by real-time PCR. After the suppression of circWHSC1 expression, the changes in the proliferation, migration, invasion, and apoptosis capacities were detected by CCK-8 assay, colony formation assay, Transwell assays, flow cytometry, and the determination of apoptosis-related proteins. The interplay among circWHSC1, miR-532-3p, and latent transforming growth factor-β binding protein 2 (LTBP2) was confirmed by luciferase reporter and biotinylated RNA pull-down assays. A nude mice xenograft tumor model was established to evaluate the anti-tumorigenic role of circWHSC1 silencing in vivo. CircWHSC1 was overexpressed in CaCx tissues and cell lines and its high expression was inversely associated with the survival rate of patients with CaCx. CircWHSC1 silencing was capable of suppressing the proliferation, metastasis, and invasion of tumor cells and inducing apoptosis. Investigation to its molecular mechanism revealed that circWHSC1 functioned as a competitive endogenous RNA (ceRNA), mediating LTBP2 expression by targeting miR-532-3p. The in vivo experiments further confirmed the inhibition of tumor growth and metastasis by circWHSC1 knockdown. The circWHSC1-mediated miR-532-3p/LTBP2 signaling axis might be a novel therapeutic target for CaCx.
- Open Access
- 18 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186965
Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
[This corrects the article DOI: 10.1371/journal.pone.0089350.].
- 18 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186965
Open AccessCorrection: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
[This corrects the article DOI: 10.1371/journal.pone.0089350.].